Hinge Health (HNGE) EBITDA Margin (2024 - 2026)

Hinge Health has disclosed EBITDA Margin across 3 years of filings, most recently posting 19.09% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 19.09%, up 529.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 81.18% (down 8503.0% YoY), and the FY2025 annual result was 89.88%, down 8682.0% from the prior year.
• EBITDA Margin came in at 19.09% for Q1 2026 at Hinge Health, up from 15.96% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 19.09% in Q1 2026 to a low of 417.45% in Q2 2025.
• The 3-year median for EBITDA Margin is 4.99% (2025), against an average of 47.26%.
• Across the five-year window, EBITDA Margin sank 39792 bps in 2025 and soared 529 bps in 2026, its largest moves.
• Hinge Health's EBITDA Margin stood at 17.83% in 2024, then slipped by 10 bps to 15.96% in 2025, then advanced by 20 bps to 19.09% in 2026.
• The last three EBITDA Margin figures came in at 19.09% (Q1 2026), 15.96% (Q4 2025), and 3.95% (Q3 2025), per Business Quant data.